Lv4
770 积分 2021-07-11 加入
Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
1个月前
已完结
Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 “DICIPLE” Phase III trial
2个月前
已关闭
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker exploration
3个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
4个月前
已完结
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
4个月前
已完结
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
4个月前
已完结
The TNM Classification of Malignant Tumours, 8th Edition
5个月前
已关闭
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis
6个月前
已完结
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
6个月前
已完结
Diagnostic Advances and Novel Therapeutics in Peritoneal Metastasis
7个月前
已关闭
皖公网安备34019202002308
